Skip to content
Stock screener

CALC CalciMedica, Inc. stock chart & analysis

Conviction 45HealthcareScan · Tue, Nov 17, 2026

CalciMedica, Inc. (CALC) closed at $1.23 (+2.94%) on Nov 17, 2026. Price is below its 50-day and below its 200-day moving average. RSI(14) 43, RS Rating 4, -96.6% from its 52-week high, -96.3% year to date. Sector: Healthcare · Pharmaceutical Preparations.

CALC$1.23+2.94%
ResistanceSupportVol 14Insider buy
Loading chart…

Why CALC moved

From the StockSetups movers recaps that covered CALC, newest first. A recap states what was known that day.

CalciMedica, Inc.Pharmaceutical Preparationswww.calcimedica.com ↗
Price1.23
Change+2.94%
Gap+2.94%
Rel volume0.00×
Avg volume82.68K
Avg $ vol113.69K
SMA 201.34
SMA 501.50
SMA 2002.95
Price vs 50-18.28%
Price vs 200-58.43%
MA stackbearish
50/200 cross—
Supertrendup · 1.14
RSI (14)43
MACD hist-0.00
MACD crossbear · 1d
Stoch %K / %D13 / 10
ADX (14)21
+DI / −DI19 / 22
RSI divergence—
MACD divergence—
ATR %14.90%
ADR %14.72%
52w high36.00
52w low1.00
From 52w high-96.60%
Above 52w low+22.50%
New 52w highNo
SqueezeOff
Bollinger width47.22%
%B0.31
Donchian pos20.13%
Donchian high1.84
Donchian low1.07
AVWAP (52w high)4.24
vs AVWAP high-71.13%
AVWAP (52w low)1.38
vs AVWAP low-11.28%
OBV trendUp
Chaikin MF (20)-0.19
Today vs 20d0.00×
Avg vol (14d)62.05K
Avg vol (20d)82.68K
Avg $ vol (20d)113.69K
Market cap8.45M
RS Rating4 / 99
RS 3m (vs SPY)-55.28%
RS 6m (vs SPY)-60.14%
RS line new highNo
Trend template0/8
Technical rank29.6
1 week-10.58%
1 month+20.10%
3 months-60.04%
6 months-60.32%
1 year-91.83%
YTD-96.28%
P/E-0.29
P/B2.00
P/S—
P/FCF-0.40
EPS-1.97
Div yield—
ROE-699.36%
ROA-206.81%
Debt/Eq—
Current4.96
EV/EBITDA—
Gross margin—
Net margin—
Rev growth—
EPS growth-115.78%
Price target—
Target upside—
Analyst rating—
Institutional—
Ent. value3.87M
Revenue—
Net income-1.67M
Gross profit—
Free cash flow-21.21M
IndustryPharmaceutical Preparations
ExchangeNasdaq
Shares out15.8M
Employees16
ListedFri, Sep 25, 2020
Free float5.73M
Float %39.8%
Short interest—
Days to cover—
Short volume59.1%
Squeeze score—
Next earnings—
EPS forecast—
Last EPS vs est—
Last surprise—
Setup gradeD
Conviction45 / 100
Pattern quality—
Tech rank29.6 / 100
Group rank14 / 100
Status laneNo active setup
Setup direction—
Pattern family
Resistance1.77
Support1.02
Days since event—
Candle confirm—

Financials as of Wed, Sep 30, 2026 · quarterly.

CALC technical analysis

Trend

CALC is in a downtrend: price is below the 50-day, which is below the 200-day moving average. It closed 18.3% below the 50-day ($1.50) and 58.4% below the 200-day ($2.95). ADX(14) at 21 points to a moderate trend. It meets 0 of 8 trend-template criteria.

Momentum

RSI(14) is 43, in the bearish half of its range. MACD crossed below its signal line one session ago. Its RS Rating of 4 puts its weighted 12-month performance ahead of about 4% of the US market.

Volume and volatility

Volume on the latest session ran 0.0× its 20-day average. It trades about $113,689 a day on average. ATR(14) is $0.1825, 14.9% of price — its typical daily range. On-balance volume is trending up. Chaikin Money Flow (-0.19) shows distribution.

Key levels

The chart pattern's support is $1.02 and its resistance $1.77. The 52-week range is $1.00 to $36.00; price is 96.6% below the high and 22.5% above the low. The VWAP anchored at the 52-week high is $4.24, above price.

Performance

CALC returned -10.6% (1 week), +20.1% (1 month), -60.0% (3 months), -60.3% (6 months), -91.8% (1 year), -96.3% (year to date).

About CalciMedica, Inc.

CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys. The company operates as one operating segment focused on developing and commercializing therapeutics in the U.S.

Pharmaceutical Preparations · Listed 2020 · 16 employees

Insider activity

SEC Form 4 transactions in CALC

InsiderSideShares
Roberts Eric W
CHIEF BUSINESS OFFICER · Employee Stock Option (Right to Buy) · 2026-11-03
Grant180K
WILSON ROBERT N
Director · Director Stock Option (Right to Buy) · 2026-10-01
Grant20K
Shaw Allan
Director · Director Stock Option (Right to Buy) · 2026-10-01
Grant20K
Zaytsev Evgeny
Director · Director Stock Option (Right to Buy) · 2026-10-01
Grant20K
Glicklich Alan
Director · Director Stock Option (Right to Buy) · 2026-10-01
Grant20K
Guerard Frederic
Director · Director Stock Option (Right to Buy) · 2026-10-01
Grant20K
ALAFI CAPITAL CO LLC
10% owner · Series A Warrants · 2026-08-19
Grant3.53M
ALAFI CAPITAL CO LLC
10% owner · Series B Warrants · 2026-08-19
Grant3.53M
WILSON ROBERT N
Director · Warrant · 2026-08-19
Grant1.18M
WILSON ROBERT N
Director · Director Stock Option (Right to Buy) · 2026-08-19
Grant10K

SEC filings

EDGAR filings in CALC · 10 recent

EDGAR →

Get daily signals & real-time alerts.

StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 7 days, no credit card.

Start free — 7-day trial, no card →

Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.